Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Center, Multi-Dose, Randomized, Open-Label, Parallel Group Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

NCT00297713 is registered in ClinicalTrials.gov with Altus Pharmaceuticals as lead sponsor.

NCT NCT00297713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00297713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Center, Multi-Dose, Randomized, Open-Label, Parallel Group Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety
Lead sponsor
Altus Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
June 30, 2006
Enrollment
12
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adult growth hormone deficiency